Antibiotics are the infrastructure of modern medicine. Without them, routine surgery carries lethal infection risk. Chemotherapy cannot proceed. Childbirth becomes dangerous again. Organ transplants fail. The drugs that made the 20th century’s greatest medical achievements possible are losing their power — and almost nothing is replacing them. That is what the global antibiotic resistance crisis actually means.

The Pipeline Crisis — We Are Running Out of Antibiotics and Not Making New Ones

Here is the core structural problem. Bacteria evolve resistance to every antibiotic eventually. That has always been true. What changed is that the pharmaceutical pipeline — the process of discovering and developing new antibiotics — has nearly stopped. Since 2017, public and philanthropic investment in AMR R&D has reached $13.75 billion annually. But experts say an additional $250–400 million per year is needed just to sustain development. The financial returns on antibiotics are too low to attract private investment. New antibiotics are used sparingly to preserve them — which makes them commercially unattractive. The result: fewer treatments for more resistant infections.

The Economics of Doing Nothing

Treating drug-resistant infections already costs $66 billion globally per year. Without action, the WHO projects that cost will reach $412 billion annually just for treatment by 2035 — plus an additional $443 billion in lost productivity. If resistance spreads from livestock to humans at scale, it could cost up to $5.2 trillion more. By 2050, annual global GDP losses could reach $1.7 trillion. And it could jeopardise the food security of more than 2 billion people. The economics of the antibiotic crisis are not uncertain. Every year of inaction makes the eventual cost larger.